Royal Marsden Hospital, SURRE, United Kingdom
- This delegate is presenting an abstract at this event.
Dr Ian Chau holds the position of consultant medical oncologist within the Gastrointestinal and Lymphoma Units at Royal Marsden Hospital and honorary senior lecturer at the Institute of Cancer Research, London & Surrey, UK. He qualified from the United Medical & Dental Schools of Guy’s and St. Thomas’ Hospitals, University of London, before undergoing medical oncology specialist training and clinical research fellowship at the Royal Marsden Hospital. His main research interests are clinical trials and translational research in gastrointestinal cancers and lymphoma. He is the principal investigator of multiple phase I, II and III clinical trials evaluating novel treatment strategies and agents in various cancer signalling pathways. He serves on the committees for the UK National Cancer Research Institute (NCRI) Colorectal Cancer and Pancreatic Cancer Clinical Study Groups as well as the American Society of Clinical Oncology (ASCO) Scientific Program Committee. He is on the trial management groups of the UK NCRI phase III gastrointestinal cancer and lymphoma trials and International Advisory Panel for the Cancer Research UK Clinical Trials Awards & Advisory Committee. He is the recipient of merit awards from ASCO Gastrointestinal Cancer Symposium, The Royal Society of Medicine Section of Oncology Clinical Prize, fellowships from the European School of Oncology and ASCO/AACR/FECS Clinical Cancer Research Workshop. He has given invited lectures in over 20 countries. He has served on international drug development advisory boards and has peer review publications in the New England Journal of Medicine, Journal of Clinical Oncology and other leading oncology / biomedical journals.
Presentations this author is a contributor to:
What is the optimal neoadjuvant chemotherapy regimen in resectable oesophageal cancer? (#56)
Plenary: The changing face of oesophageal cancer: Moving towards individualised care
Targeted therapy in oesophago-gastric cancer (#59)
Recent advances in the management of upper gastro-intestinal cancer treatment